SCHEMBL23215744

SCHEMBL23215744

CC(C)(C)OC(=O)N1CCC(CCCOc2ccc(CC(=O)N3CC(CO)C3)c(F)c2)CC1

nearest known ligand 0.65

Predicted protein targets (top 3)

geneUniProtsupporting neighboursconfidence
▸ GPR119 Q8TDV5 16/20 0.65
▸ KCNH2 Q12809 2/20 0.49
▸ SCN9A Q15858 1/20 0.42

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL29843792 1.00 GPR119 (0.65) GPR119KCNH2SCN9A
SCHEMBL29843831 0.89 GPR119 (0.50) GPR119KCNH2
SCHEMBL23215588 0.88 GPR119 (0.48) GPR119KCNH2
SCHEMBL1922598 0.87 GPR119 (0.71) GPR119KCNH2SCN9A
SCHEMBL23214796 0.85 GPR119 (0.69) GPR119KCNH2SCN9A
SCHEMBL29843762 0.85 GPR119 (0.69) GPR119KCNH2SCN9A
SCHEMBL24437577 0.84 GPR119 (0.67) GPR119KCNH2SCN9A
SCHEMBL3226905 0.82 GPR119 (0.78) GPR119SCN9A
SCHEMBL23216209 0.81 GPR119 (0.54) GPR119KCNH2
SCHEMBL2387212 0.81 GPR119 (0.63) GPR119KCNH2SCN9A

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 9 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
CN-114945560-B GPR119 agonists 卡尔优普公司 2024-08-13 — — CN disclosed
US-20230061736-A1 GPR119 AGONISTS KALLYOPE, INC. 2023-03-02 — — US disclosed
US-20230061736-A1 GPR119 AGONISTS KALLYOPE, INC. 2023-03-02 — — US disclosed
US-11512065-B2 GPR119 agonists KALLYOPE, INC. (US) 2022-11-29 — — US disclosed
CN-114945560-A GPR119 agonists 卡尔优普公司 2022-08-26 — — CN disclosed
US-20220153719-A1 GPR119 AGONISTS KALLYOPE, INC. 2022-05-19 — — US disclosed
US-20220153719-A1 GPR119 AGONISTS KALLYOPE, INC. 2022-05-19 — — US disclosed
WO-2021071837-A1 GPR119 AGONISTS KALLYOPE, INC. (US) 2021-04-15 — — WO disclosed
WO-2021071837-A1 GPR119 AGONISTS KALLYOPE, INC. (US) 2021-04-15 — — WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-11512065-B2 GPR119 agonists GPR119, GLP1R, GCGR GPR119 1/4885KCNH2 4507/4885SCN9A 1896/4885
US-20230061736-A1 GPR119 AGONISTS GPR119, GLP1R, GCGR GPR119 1/4885KCNH2 4507/4885SCN9A 1896/4885
US-20220153719-A1 GPR119 AGONISTS GPR119, GLP1R, GCGR GPR119 1/4885KCNH2 4507/4885SCN9A 1896/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.

Send feedback